Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients24
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant19
Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center17
Evaluation of hepatotoxicity due to conditioning regimens in beta thalassemia major and aplastic anemia patients undergoing bone marrow transplantation17
Identifying health disparities in lenalidomide access16
Initial real-world experience with ribociclib in advanced breast cancer15
Exploring the potential relationship between antineoplastic agents and their association with stomatitis and oral candidiasis in cancer patients15
Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients14
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer14
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”13
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies12
Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer12
A room of errors simulation to improve pharmacy operators’ knowledge of cytotoxic drug production12
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors12
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy12
0.12944793701172